A Phase II trial of trastuzumab combined with irinotecan in patients with advanced HER2-positive chemo-refractory gastric cancer: Osaka Gastrointestinal Cancer Chemotherapy Study Group OGSG1203 (HERBIS-5)

Japanese Journal of Clinical Oncology

Volumn 43, Issue 8, 2013, Pages 838-840

  Sakai, Daisuke ^a   Satoh, Taroh ^a   Kurokawa, Yukinori ^a   Kudo, Toshihiro ^a   Nishikawa, Kazuhiro ^b   Oka, Yoshio ^c   Tsujinaka, Toshimasa ^d   Shimokawa, Toshio ^e   Doki, Yuichiro ^a   Furukawa, Hiroshi ^f  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b OSAKA GENERAL MEDICAL CENTER   (Japan)

^c Nishinomiya Municipal Central Hospital   (Japan)

^d Kaizuka City Hospital   (Japan)

^e UNIVERSITY OF YAMANASHI   (Japan)

^f KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Chemo GI tract HER2 positive; Irinotecan; Trastuzumab

Indexed keywords

IRINOTECAN; TRASTUZUMAB;

ADULT; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; DISEASE CONTROL; DRUG EFFICACY; DRUG SAFETY; HUMAN; MULTICENTER STUDY; OPEN STUDY; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PROGRESSION FREE SURVIVAL; STOMACH CANCER; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

CHEMO-GI TRACT HER2-POSITIVE; IRINOTECAN; TRASTUZUMAB;

ADULT; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; MALE; MIDDLE AGED; PATIENT SELECTION; RECEPTOR, ERBB-2; STOMACH NEOPLASMS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 84881089659     PISSN: 03682811     EISSN: 14653621     Source Type: Journal    
DOI: 10.1093/jjco/hyt083     Document Type: Article

References (17)

1. Thuss-Patience PC, Kretzschmar A, Bichev D, et al. Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer-a randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). Eur J Cancer 2011;47:2306-14.
2. Kang JH, Lee S, II, Lim DH, et al. Salvage chemotherapy for pretreated gastric cancer: a randomized phase III trial comparing chemotherapy plus best supportive care with best supportive care alone. J Clin Oncol 2012;30:1513-8.
3. Ford H, Marshall A, Wadsley J, et al. COUGAR-02: A randomized phase III study of docetaxel versus active symptom control in advanced esophagogastric adenocarcinoma. J Clin Oncol 2012;30(Suppl 34): Abstract LBA4.
4. Ueda S, Hironaka S, Yasui H, et al. Randomized phase III study of irinotecan (CPT-11) versus weekly paclitaxel (wPTX) for advanced gastric cancer (AGC) refractory to combination chemotherapy (CT) of fluoropyrimidine plus platinum (FP): WJOG4007 trial. J Clin Oncol 2012;30:4002.
5. Gravalos C, Jimeno A. HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target. Ann Oncol 2008;19:1523-9.
6. Kurokawa Y, Matsuura N, Kimura Y, et al. Survival impact of Her2 status in patients with gastric cancer: a multicenter large-scale study in Japan. Ann Oncol 2012;23:ix227.
7. Nishikawa K, Chin K, Nashimoto A, et al. Result of HER2 status in Japanese metastatic gastric cancer: prospective cohort study (JFMC44-1101). J Clin Oncol 2012;30(Suppl 34): Abstract 10.
8. Bang Y, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 2010;376:687-97.
9. Bennouna J, Sastre J, Arnold D, et al. Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial. The Lancet Oncol 2013;14:29-37.
10. Hainsworth JD, Litchy S, Shaffer DW, Lackey VL, Grimaldi M, Greco FA. Maximizing therapeutic benefit of rituximab: maintenance therapy versus re-treatment at progression in patients with indolent non-Hodgkin's lymphoma-a randomized phase II trial of the Minnie Pearl Cancer Research Network. J Clin Oncol 2005;23:1088-95.
11. Nishie K, Kawaguchi T, Tamiya A, et al. Epidermal growth factor receptor tyrosine kinase inhibitors beyond progressive disease: a retrospective analysis for Japanese patients with activating EGFR mutations. J Thorac Oncol 2012;7:1722-7.
12. Von Minckwitz G, Du Bois A, Schmidt M, et al. Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a German breast group 26/breast international group 03-05 study. J Clin Oncol 2009;27:1999-2006.
13. Blackwell KL, Burstein HJ, Storniolo AM, et al. Randomized study of lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer. J Clin Oncol 2010;28:1124-30.
14. Cardoso F, Fallowfield L, Costa A, Castiglione M, Senkus E. Locally recurrent or metastatic breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2011;22:vi25-30.
15. Fujimoto-Ouchi K, Sekiguchi F, Yasuno H, Moriya Y, Mori K, Tanaka Y. Antitumor activity of trastuzumab in combination with chemotherapy in human gastric cancer xenograft models. Cancer Chemother Pharmacol 2007;59:795-805.
16. Weissinger F, Reymond M, Dumke K, Krüger M. Successful treatment of a patient with HER2-positive metastatic gastric cancer with third-line combination therapy with irinotecan, 5-fluorouracil, leucovorin and trastuzumab (FOLFIRI-T). Onkologie 2011;34: 548-51.
17. Ito Y, Kobayashi K. Chemotherapy for breast cancer refractory to anthracycline, taxane or trastuzumab. Gan to kagaku ryoho 2009;36:726-9. (in Japanese).